Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001636282-25-000038
Filing Date
2025-04-14
Accepted
2025-04-14 16:33:28
Documents
21
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A syre-20250414.htm   iXBRL DEF 14A 532050
6 syre-20250414_g1.jpg GRAPHIC 24936
7 syre-20250414_g2.jpg GRAPHIC 242845
8 syre-20250414_g3.jpg GRAPHIC 261047
9 syre-20250414_g4.jpg GRAPHIC 468660
10 syre-20250414_g5.jpg GRAPHIC 262690
  Complete submission text file 0001636282-25-000038.txt   4075819

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20250414.xsd EX-101.SCH 3253
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT syre-20250414_def.xml EX-101.DEF 4309
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20250414_lab.xml EX-101.LAB 5261
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20250414_pre.xml EX-101.PRE 4169
23 EXTRACTED XBRL INSTANCE DOCUMENT syre-20250414_htm.xml XML 129209
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 25836423
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)